Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2024
2023
2022
2021
2020
2019
-
Sep 24,2024
HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical Trial
Learn More
-
Sep 09,2024
HuidaGene Therapeutics Announces the Appointment of Dr. Xin Zhang as Chief Operations Officer and Chief Medical Officer to Further Strengthen the Management Team
Learn More
-
Sep 02,2024
HuidaGene to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2024 Annual Meeting
Learn More
-
Jun 11,2024
NovoCrops and HuidaGene enter licensing partnership to expedite gene editing crop development
Learn More
-
May 31,2024
HuidaGene Therapeutics to Attend 2024 BIO International Convention in California for Actively Expanding Global Collaboration
Learn More
-
May 29,2024
HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max
Learn More
-
May 06,2024
HuidaGene Therapeutics Receives European Medicines Agency Orphan Designation for HG204 to Treat MECP2 Duplication Syndrome
Learn More
-
Apr 22,2024
HuidaGene Orally Presents Data Highlighting Strength of Ophthalmology Portfolio at the 2024 Association for Research in Visual and Ophthalmology Annual Meeting
Learn More
-
Apr 15,2024
HuidaGene Therapeutics to Open Up the First CRISPR MEDiCiNE European Conference
Learn More